GeneDx Expands NPC Testing Access with Zevra via ExomeDx and Infinity Dataset
GeneDx Holdings launched a genetic testing program with Zevra Therapeutics to expand access to its ExomeDx exome sequencing test for suspected Niemann-Pick Disease type C cases, leveraging the GeneDx Infinity dataset. The collaboration aims to accelerate diagnosis by enabling clinicians to confirm NPC mutations with precision and identify patients earlier.
1. Program Launch
GeneDx has launched a genetic testing program in collaboration with Zevra Therapeutics to expand access to ExomeDx testing for suspected Niemann-Pick Disease type C cases. The initiative is designed to remove barriers to high-quality exome sequencing in clinical settings.
2. ExomeDx and Infinity Dataset
The program leverages GeneDx’s Infinity dataset, the world’s largest rare-disease genomic repository, to refine diagnostic algorithms and enable more precise identification of NPC1 and NPC2 gene mutations. Clinicians will gain earlier insights into disease biology and patient eligibility for emerging therapies.
3. Strategic Implications for GeneDx
This partnership enhances GeneDx’s presence in the rare-disease market and could drive incremental testing volumes and revenue growth. By collaborating with a biopharma partner on patient identification, GeneDx strengthens its commercial model and accelerates its role in precision medicine.